EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation

Ran Hu iD, Benjamin Tran, Shuo Li, Mary L Stackpole iD, Weihua Zeng, Yonggang Zhou, Andrew Melehy, Saeed Sadeghi, Richard S Finn, Xianghong Jasmine Zhou, Wenyuan Li, Vatche G Agopian

PLOS One · 2025

DOI: 10.1371/journal.pone.0321736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ran Hu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, U…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, DNA Methylation, Liver Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The current noninvasive prognostic evaluation methods for hepatocellular carcinoma (HCC), which are largely reliant on radiographic imaging features and serum biomarkers such as alpha-fetoprotein (AFP), have limited effectiveness in discriminating patient outcomes. Identification of new prognostic biomarkers is a critical unmet need to improve treatment decision-making. Epigenetic changes in cell-free DNA (cfDNA) have shown promise in early cancer diagnosis and prognosis. Thus, we aim to evaluate the potential of cfDNA methylation as a noninvasive predictor for prognostication in patients with active, radiographically viable HCC.

Methods

Using Illumina HumanMethylation450 array data of 377 HCC tumors and 50 adjacent normal tissues obtained from The Cancer Genome Atlas (TCGA), we identified 158 HCC-related DNA methylation markers associated with overall survival (OS). This signature was further validated in 29 HCC tumor tissue samples. Subsequently, we applied the signature to an independent cohort of 52 patients with plasma cfDNA samples by calculating the cfDNA methylation-based risk score (methRisk) via random survival forest models with 10-fold cross-validation for the prognostication of OS.

Results

The cfDNA-based methRisk showed strong discriminatory power when evaluated as a single predictor for OS (3-year AUC = 0.81, 95% CI: 0.68–0.94). Integrating the methRisk with existing risk indices like Barcelona clinic liver cancer (BCLC) staging significantly improved the noninvasive prognostic assessments for OS (3-year AUC = 0.91, 95% CI: 0.80–1), and methRisk remained an independent predictor of survival in the multivariate Cox model (P = 0.007).

Conclusions

Our study serves as a pilot study demonstrating that cfDNA methylation biomarkers assessed from a peripheral blood draw can stratify HCC patients into clinically meaningful risk groups. These findings indicate that cfDNA methylation is a promising noninvasive prognostic biomarker for HCC, providing a proof-of-concept for its potential clinical utility and laying the groundwork for broader applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularDNA MethylationLiver NeoplasmsBiomarkers, TumorCell-Free Nucleic AcidsHumansFemaleMalePrognosisMiddle AgedAged

Substanzen

Biomarkers, TumorCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, United States of America.
  • Bioinformatics Interdepartmental Graduate Program, University of California at Los Angeles, Los Angeles, California, United States of America.
  • Institute for Quantitative and Computational Biosciences, University of California at Los Angeles, Los Angeles, California, United States of America.
  • Department of Surgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, United States of America.
  • Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, United States of America.
  • Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, United States of America.

ORCID-Profile: Ran Hu, Mary L Stackpole

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Hu, R., Tran, B., Li, S., Stackpole, M. L., Zeng, W., Zhou, Y., Melehy, A., Sadeghi, S., Finn, R. S., Zhou, X. J., Li, W., & Agopian, V. G. (2025). Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation. PLOS One. https://doi.org/10.1371/journal.pone.0321736

Vancouver

Hu R, Tran B, Li S, Stackpole ML, Zeng W, Zhou Y, et al. Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation. PLOS One. 2025. doi:10.1371/journal.pone.0321736

BibTeX
@article{Hu2025,
  author = {Hu, Ran and Tran, Benjamin and Li, Shuo and Stackpole, Mary L and Zeng, Weihua and Zhou, Yonggang and Melehy, Andrew and Sadeghi, Saeed and Finn, Richard S and Zhou, Xianghong Jasmine and Li, Wenyuan and Agopian, Vatche G},
  title = {Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0321736}
}
Kostenlos starten →